While menin inhibitors have shown significant promise in targeting KMT2Ar and NPM1mut AML, the complexity and redundancy of oncogenic pathways in these leukemias often lead to resistance, underscoring the need for combination therapies. Here, MEN1 is linked to acute myeloid leukemia.